Grufity logo
Grufity logo
ARWR

ARWR - Arrowhead Pharmaceuticals Inc Stock Price, Fair Value and News

$83.67-1.86 (-2.17%)
Delayed as of 28 Jul 2026, 02:03 pm ET

13/100

ARWR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

13/100

ARWR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ARWR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ARWR Price Action

Last 7 days

19.4%

Last 30 days

8.4%

Last 90 days

22.0%

Trailing 12 Months

443.5%

ARWR RSI Chart

ARWR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ARWR Valuation

Market Cap

12.0B

Price/Earnings (Trailing)

-39.84

Price/Sales (Trailing)

19.37

EV/EBITDA

-47.41

Price/Free Cashflow

-236.82

ARWR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ARWR Fundamentals

ARWR Revenue

Revenue (TTM)

622.0M

Rev. Growth (Yr)

-86.41%

Rev. Growth (Qtr)

-72.07%

ARWR Earnings

Earnings (TTM)

-302.4M

Earnings Growth (Yr)

-135.83%

Earnings Growth (Qtr)

-569.98%

ARWR Profitability

EBT Margin

-40.56%

Return on Equity

-49.26%

Return on Assets

-13.33%

Free Cashflow Yield

-0.42%

ARWR Investor Care

Shares Dilution (1Y)

9.14%

Diluted EPS (TTM)

-2.12

Revenue & Growth

How Arrowhead Pharmaceuticals Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026622.0M---
2025--829.4M1.1B
2024----
2023272.8M256.2M240.7M-
2022263.4M249.9M243.2M278.3M
202189.1M107.6M138.3M144.4M
2020139.0M123.7M88.0M79.8M
201994.8M136.8M168.8M163.6M
201822.2M13.6M16.1M47.3M
201718.9M25.2M31.4M30.6M
2016255.0K170.8K6.4M12.7M
2015302.0K382.0K382.0K255.0K
2014175.0K175.0K175.0K302.0K
2013294.4K290.3K290.3K175.0K
201255.2K103.1K146.9K281.9K
2011--296.1K24.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Arrowhead Pharmaceuticals Inc

ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
 CEO
 WEBSITEhttps://arrowheadpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES397

Arrowhead Pharmaceuticals Inc Frequently Asked Questions

ARWR is the stock ticker symbol of Arrowhead Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jul 27 2026, market cap of Arrowhead Pharmaceuticals Inc is 12.05 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jul 27 2026, ARWR's PE ratio (Price to Earnings) is -39.84 and Price to Sales (PS) ratio is 19.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARWR PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Arrowhead Pharmaceuticals Inc has provided 0.305 (multiply by 100 for percentage) rate of return.